Literature DB >> 12094266

ABL-specific tyrosine kinase inhibitor imatinib as salvage therapy in a child with Philadelphia chromosome-positive acute mixed lineage leukemia (AMLL).

B Selle, C Bär, S Hecker, U Schmidt-Rohr, S Viehmann, K-M Debatin, D Reinhardt.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12094266     DOI： 10.1038/sj.leu.2402520

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  1 in total

1.  Successful treatment of Philadelphia chromosome-positive mixed phenotype acute leukemia by appropriate alternation of second-generation tyrosine kinase inhibitors according to BCR-ABL1 mutation status.

Authors:  Chika Kawajiri; Hiroaki Tanaka; Shinichiro Hashimoto; Yusuke Takeda; Shio Sakai; Toshiyuki Takagi; Masahiro Takeuchi; Chikako Ohwada; Emiko Sakaida; Naomi Shimizu; Chiaki Nakaseko
Journal:  Int J Hematol       Date:  2014-02-15       Impact factor: 2.490
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.